CAR T Cell Therapy for acute leukaemia: The RCH experience as the national paediatric referral centre
Chimeric Antigen Receptor (CAR) T cells have revolutionised treatment for patients with acute lymphoblastic leukaemia (ALL) where standard therapies have failed. We reflect on our first 12 months as the first national paediatric referral centre providing CAR T cell treatment to children with relapsed or refractory ALL from Australia and New Zealand, and highlight the collective efforts and lessons for the hospital-wide CAR T cell team.